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Figure 1. Cumulative incidence of relapse according to CD4+ immune recon-
stitution in myeloid leukemia
Figure 2. Non-relapse mortality according to CD4+ immune reconstitution in
all patients271
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Background: Relapse of leukemia after pediatric hemato-
poietic cell transplantation (HCT) is a frequent cause of
treatment failure. Immune reconstitution (IR) early after HCT
is pivotal to generate a potent graft-versus-leukemia effect.
We studied the association between IR of various lympho-
cyte subsets and outcomes in children receiving a cord blood
HCT for hematological malignancies.
Methods: All consecutive patients with a hematological
malignancy receiving a cord blood HCT between 2004-2014
at Great Ormond Street Hospital London and at the UMC
Utrecht were included. Patients received a myeloablative
regimen  Thymoglobulin. Primary endpoint was relapse;
secondary endpoints were overall survival, non-relapse
mortality (NRM), acute GvHD (grade 2-4) and chronic GvHD.
Lymphocyte-subsets (CD3+, CD4+, CD8+, NK and B-cells)
weremonitored every other week after engraftment. Various
deﬁnitions of IR were analyzed including one in line with a
reported association: CD4+ T-cell count >50/mL in 2
consecutive measurements within 100 days post-HCT (Bar-
telink et al, BBMT 2013). Cox proportional hazardmodels and
logistic regression models were used.
Results: 89 patients were included, with a median age of 7.1
years (range0.7-18): 36ALL (19CR1,14CR2, 3 CR3), 49AML (14
refractory, 35 CR) and 4 other malignancies. 36 patients
received Thymoglobulin (Utrecht only). CD4-IR (count >50,
twice <100 days) was the best predictor for endpoints; in
multivariate (MV) analyses, CD4-IR was a predictor for lower
probability of relapse in AML patients (MV: HR 0.29, 95% CI
0.03-0.98, p¼0.04; ﬁgure 1), but not in ALL (p¼0.14). CD4-IR
was also a predictor for NRM (MV: HR 0.13, 95% CI 0.03-0.52,
p¼0.004; ﬁgure 2). CD4-IR predicted OS in AML (MV: HR
0.17, 95% CI 0.06-0.53, p¼0.002), but not in ALL. However,
CD4-IR did not have an impact on acute grade 2-4 (p¼0.41)
or chronic GvHD (p¼0.12). Successful CD4-IR was less
frequent in patients receiving Thymoglobulin (MV: OR 0.04,
95% CI 0.002-0.27, p¼0.005). Associations with the endpoints
for the other lymphocyte-subsets were less predictive.
Conclusion: Early CD4-IR post cord blood HCT predicts the
probability of relapse in AML as well as NRM in all patients.
Thymoglobulin negatively impacts CD4-IR post cord bloodHCT, hence the use and/or the dosing of Thymoglobulin
should be carefully re-considered.272
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